News
TipRanks on MSN19h
Regeneron and Sanofi’s Phase 3 Study on Itepekimab: A Potential Game-Changer for Chronic Rhinosinusitis TreatmentRegeneron Pharmaceuticals and Sanofi are conducting a Phase 3 clinical study titled A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Phase 3 Trial to Invest ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback